KELIX Bio Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
KELIX Bio Limited - overview
Established
2020
Location
London, -, UK
Primary Industry
Pharmaceuticals
About
Based in London, UK, and founded in 2020 by Chief Executive Officer Hocine Sidi and Chief Strategy Officer Alhadi Alwazir, Kelix bio-Limited operates as a pharmaceutical based company providing engages in the development and commercialization of specialty pharmaceutical products. In March 2024, Mubadala Investment Company agreed to acquire KELIX Bio Limited. Kelix bio-Limited specializes in a specialty generic development and commercializing affordable specialty products. The company operates through various subsidiaries, each contributing to its overarching mission.
Adwia, based in Cairo, is Egypt's leading generics pharmaceutical company, specializing in CNS, men's health pain, and anti-infectives. Celon Labs, headquartered in Hyderabad, India, is renowned for its expertise in Oncology and Critical Care medications, serving both domestic and international markets. KELIX bio-Malta operates a cutting-edge manufacturing facility dedicated to producing liquid and freeze-dried cytotoxic drug products, with certifications from US FDA and EMA. PHI, based in Rabat, Morocco, focuses on importation, manufacturing, and promotion of branded pharmaceutical products, with a strong presence in French West Africa.
Current Investors
British International Investment, Development Partners International, EBRD
Primary Industry
Pharmaceuticals
Sub Industries
Specialty Pharmaceuticals
Website
www.kelixbio.com
Verticals
Manufacturing
Total Amount Raised
Subscriber access only
KELIX Bio Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on, Corporate Carve Out, LP Direct | Completed | DiabTec LLC | - | ||||||||
| Add-on, Corporate Carve Out, LP Direct | Completed | Bioventure FZ LLC, Bioventure Healthcare FZE, Gulf Inject, Wellpharma Medical Solutions | - | ||||||||
| LP Direct, Trade Sale | Completed | KELIX Bio Limited | - | ||||||||
| Company Formation | Completed | KELIX Bio Limited | - |
Displaying 1 - 4 of 4
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.